BRPI0410503B8 - composição tópica e uso da composição - Google Patents

composição tópica e uso da composição

Info

Publication number
BRPI0410503B8
BRPI0410503B8 BRPI0410503A BRPI0410503A BRPI0410503B8 BR PI0410503 B8 BRPI0410503 B8 BR PI0410503B8 BR PI0410503 A BRPI0410503 A BR PI0410503A BR PI0410503 A BRPI0410503 A BR PI0410503A BR PI0410503 B8 BRPI0410503 B8 BR PI0410503B8
Authority
BR
Brazil
Prior art keywords
composition
topical
ivermectin
pharmaceutical composition
topical pharmaceutical
Prior art date
Application number
BRPI0410503A
Other languages
English (en)
Portuguese (pt)
Inventor
R Watkins Gary
Manetta Vincent
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410503(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BRPI0410503A publication Critical patent/BRPI0410503A/pt
Publication of BRPI0410503B1 publication Critical patent/BRPI0410503B1/pt
Publication of BRPI0410503B8 publication Critical patent/BRPI0410503B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0410503A 2003-04-24 2004-04-22 composição tópica e uso da composição BRPI0410503B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR03/05048 2003-04-24
US46899403P 2003-05-09 2003-05-09
US60/468,994 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Publications (3)

Publication Number Publication Date
BRPI0410503A BRPI0410503A (pt) 2006-06-20
BRPI0410503B1 BRPI0410503B1 (pt) 2018-07-10
BRPI0410503B8 true BRPI0410503B8 (pt) 2021-05-25

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410503A BRPI0410503B8 (pt) 2003-04-24 2004-04-22 composição tópica e uso da composição

Country Status (16)

Country Link
US (6) US7550440B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1620113B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5711867B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101187231B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2004231323C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0410503B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2522579C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1111797T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR15C0069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1500048I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1620113I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92915I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05011208A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL1620113T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2350333C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004093886A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
US7648711B2 (en) * 2003-05-25 2010-01-19 Yuwan Wang Dimethicone-containing sustained release injection formulation
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) * 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
FR2907013B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
US20100093652A1 (en) * 2006-10-12 2010-04-15 Topaz Pharmaceuticals Inc. Preservative System for Emulsion-Based Therapeutic Topical Formulations
CA2666365C (en) 2006-10-12 2016-08-09 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
CA2745457A1 (fr) * 2008-12-23 2010-07-01 Galderma S.A. Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9233118B2 (en) * 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
KR102321169B1 (ko) 2013-08-08 2021-11-02 노반, 인크. 국소 조성물 및 그의 사용 방법
WO2015079016A1 (en) 2013-11-29 2015-06-04 Galderma Sa Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US20170232024A1 (en) * 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) * 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
US10849854B2 (en) 2015-10-13 2020-12-01 Galderma S.A. Process for preparing a composition comprising a high concentration of one or more avermectins
CA3000898A1 (en) * 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
CN109789118B (zh) * 2016-08-04 2022-09-02 盖尔德玛控股有限公司 用于治疗或预防红斑痤疮的组合物及其用途
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
US11234959B2 (en) 2016-11-03 2022-02-01 Galderma Holding SA Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
WO2018231863A1 (en) * 2017-06-12 2018-12-20 Lakewood Amedex, Inc Bisphosphocin gel formulations and uses thereof
EP4397375A3 (en) 2017-12-15 2024-09-25 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
SG11202102783QA (en) * 2018-09-28 2021-04-29 Galderma Res & Dev Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
MX2021012399A (es) 2019-04-12 2021-12-10 Ecolab Usa Inc Limpiador antimicrobiano multiuso y métodos de fabricación y uso de este.
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
EP4017474A1 (en) * 2019-08-21 2022-06-29 Timber Pharmaceuticals, Inc. Solvent delivery system for topical delivery of active agents
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
EP1154755A4 (en) * 1999-01-25 2003-08-13 Optime Therapeutics Inc Liposomes FORMULATIONS
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
CA2473760C (en) * 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
AU2003225651A1 (en) * 2002-03-04 2003-09-22 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Also Published As

Publication number Publication date
FR15C0069I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-04
US8415311B2 (en) 2013-04-09
RU2005136438A (ru) 2006-05-27
LU92915I2 (fr) 2016-02-17
KR101187231B1 (ko) 2012-10-02
US8093219B2 (en) 2012-01-10
US7550440B2 (en) 2009-06-23
AU2004231323B2 (en) 2009-12-10
JP2006524212A (ja) 2006-10-26
HUS1500048I1 (hu) 2017-10-30
JP5538461B2 (ja) 2014-07-02
CY1111797T1 (el) 2015-10-07
CA2522579C (en) 2012-08-28
AU2004231323A1 (en) 2004-11-04
WO2004093886A1 (en) 2004-11-04
BRPI0410503B1 (pt) 2018-07-10
US20130209381A1 (en) 2013-08-15
AU2004231323C1 (en) 2016-11-03
BRPI0410503A (pt) 2006-06-20
FR15C0069I2 (fr) 2016-04-22
RU2350333C2 (ru) 2009-03-27
US8080530B2 (en) 2011-12-20
PL378932A1 (pl) 2006-06-12
CY2016031I1 (el) 2017-03-15
CY2016031I2 (el) 2017-03-15
CA2522579A1 (en) 2004-11-04
US20090227668A1 (en) 2009-09-10
US20120077766A1 (en) 2012-03-29
US8470788B2 (en) 2013-06-25
KR20060004667A (ko) 2006-01-12
PL1620113T3 (pl) 2011-10-31
LTC1620113I2 (lt) 2018-02-26
US20090252797A1 (en) 2009-10-08
JP2012126738A (ja) 2012-07-05
EP1620113B1 (en) 2011-07-13
RU2350333C3 (ru) 2018-08-24
US20120258062A1 (en) 2012-10-11
US8598129B2 (en) 2013-12-03
JP5711867B2 (ja) 2015-05-07
MXPA05011208A (es) 2005-12-14
US20060100165A1 (en) 2006-05-11
EP1620113A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
BRPI0410503B8 (pt) composição tópica e uso da composição
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
BRPI0114927B8 (pt) composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
DOP2002000429A (es) Imidazotriazinas
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
PA8529701A1 (es) Compuestos retinoides
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0210650A (pt) Tablete, e, uso do mesmo
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
UY29417A1 (es) Agentes endoparasiticidas
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
PT1220676E (pt) Prevencao do cancro colorrectal
HN2003000104A (es) Derivados de ciclopenteno
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma
BRPI0512316A (pt) métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
BRPI0408322A (pt) uso de um fibrato e orlistat para o tratamento da obesidade
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
BR0309684A (pt) O tratamento de dor com ifendropil

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2824 DE 18/02/2025 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/04/2024